Alpha-mannosidase Inhibitors
1 drugsAbout Alpha-mannosidase
Alpha-mannosidase is an enzyme involved in processing N-linked glycans, which are complex sugar molecules attached to proteins. These glycans are critical for protein folding, stability, and trafficking within cells, ensuring proper cellular function.
Alpha-mannosidase is a potential drug target due to its role in glycan processing, though there is currently no genetic evidence directly linking it to specific diseases. Aberrant glycan processing contributes to pathology, making it relevant to therapeutic intervention.
LAMZEDE is the only FDA-approved drug targeting alpha-mannosidase, developed by CHIESI FARMACEUTICI SPA. It is classified as a biologic (other) and addresses a therapeutic area classified as 'Other'.
Top Alpha-mannosidase Drugs
CHIESI FARMACEUTICI SPA is the only company with an approved drug targeting alpha-mannosidase.
Low competition may indicate high entry barriers or limited market potential, requiring careful evaluation.
Alpha-mannosidase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Alpha-mannosidase, using enzyme modality.
The lack of modality diversity suggests an opportunity to explore small molecule or alternative biologic approaches.
Alpha-mannosidase Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Alpha-mannosidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 3 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Alpha-mannosidase Drug Approval Timeline (2023 - 2023)
LAMZEDE was the first and most recent drug approved in 2023, representing a 1-year span.
Recent approval suggests a nascent market; monitor clinical outcomes and market adoption to assess future potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Alpha-mannosidase. A trial counts if an approved drug acting on Alpha-mannosidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.